Approvals· Brief · November 13, 2026, 7:03 AM ET

EMA recommends approval of seven new medicines at CHMP meeting

The Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for Aumseqa, Baxfendy, Zybrivo, Garzulys, Donrafylix, Fondaparinux sodium Evumed, and Ruxolitinib Krka. The recommendations cover treatments for non-small cell lung cancer, hypertension, non-squamous non-small cell lung cancer, diabetes, venous thromboembolism, and myelofibrosis, among others.

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation